Strategic question
How should we track competitor activity across obesity, diabetes and cardiovascular disease to support global strategic decisions?
How Galen Growth helped
From market signal to decision-ready evidence
Using HealthTech Alpha’s structured intelligence layer, Galen Growth tracked five priority competitors across the US, EU5, UK, China and adjacent markets over a 12-month programme. We delivered curated alerts, bespoke workspaces and bi-monthly executive decision memos to create a consistent view of competitor movement.
Outcomes
Leadership gained a traceable, source-grounded view of competitor activity across priority therapeutic areas and geographies, reducing fragmented signal and improving cross-franchise alignment.
Decision enabled: Enabled leadership to make faster, more defensible portfolio and competitive-response decisions across core franchise areas.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Prioritising Markets and Partners to Accelerate a Women’s Health Roadmap
Which priority markets and venture partners should anchor our future women’s health innovation roadmap, starting with telemedicine?
Benchmarking Global Competitor Partnerships to Prioritise Digital Health Strategy
Where are competitors investing and partnering in Digital Health, and what should that mean for our own portfolio strategy?
Informing Franchise-Level Resource Allocation Across APAC
Which APAC markets should we prioritise for Digital Health investment, and where is our franchise readiness strongest?